



## **THE JACKSON LABORATORY**

Independent Auditors' Reports, as Required by Title 2  
U.S. Code of Federal Regulations Part 200, *Uniform Administrative  
Requirements, Cost Principles, and Audit Requirements for Federal  
Awards and Government Auditing Standards* and Related Information

Year Ended December 31, 2019

## THE JACKSON LABORATORY

Independent Auditors' Reports as Required by Title 2  
U.S. Code of Federal Regulations Part 200, *Uniform Administrative  
Requirements, Cost Principles, and Audit Requirements for Federal  
Awards and Government Auditing Standards* and Related Information

### Table of Contents

	<b>Page</b>
Independent Auditors' Report on Compliance for Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance	1
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	3
Schedule of Findings and Questioned Costs	5
Consolidated Financial Statements and Supplementary Schedule of Expenditures of Federal Awards	6



KPMG LLP  
Two Financial Center  
60 South Street  
Boston, MA 02111

**Independent Auditors' Report on Compliance for Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance**

The Board of Trustees  
The Jackson Laboratory:

*Report on Compliance for Major Federal Program*

We have audited The Jackson Laboratory's (the Laboratory's) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on the Laboratory's major federal program for the year ended December 31, 2019. The Laboratory's major federal program is identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

*Management's Responsibility*

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

*Auditors' Responsibility*

Our responsibility is to express an opinion on compliance for the Laboratory's major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Laboratory's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the Laboratory's major federal program. However, our audit does not provide a legal determination of the Laboratory's compliance.

*Opinion on Major Federal Program*

In our opinion, the Laboratory complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31, 2019.

*Report on Internal Control Over Compliance*

Management of the Laboratory is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Laboratory's internal control over compliance with the types of requirements that could have a direct and material effect on its major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for its major



federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Laboratory's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance*

We have audited the consolidated financial statements of the Laboratory as of and for the year ended December 31, 2019, and have issued our report thereon dated May 19, 2020, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of expenditures of federal awards is presented for purposes of additional analysis, as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

*KPMG LLP*

June 12, 2020



KPMG LLP  
Two Financial Center  
60 South Street  
Boston, MA 02111

**Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards**

The Board of Trustees  
The Jackson Laboratory:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of The Jackson Laboratory (the Laboratory), which comprise the consolidated balance sheet as of December 31, 2019, the related consolidated statements of activities and consolidated cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated May 19, 2020.

*Internal Control over Financial Reporting*

In planning and performing our audit of the consolidated financial statements, we considered the Laboratory's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Laboratory's internal control. Accordingly, we do not express an opinion on the effectiveness of the Laboratory's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audits we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

*Compliance and Other Matters*

As part of obtaining reasonable assurance about whether the Laboratory's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of consolidated financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



*Purpose of this Report*

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Laboratory's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Laboratory's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

May 19, 2020

**THE JACKSON LABORATORY**  
Schedule of Findings and Questioned Costs  
Year ended December 31, 2019

**(1) Summary of Auditors' Results**

*Financial Statements*

- a) Type of report issued on whether the financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- b) Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
  - Material weaknesses: **No**
  - Significant deficiencies: **None reported**
- c) Noncompliance material to the financial statements: **No**

*Federal Awards*

- d) Internal control deficiencies over major program disclosed by the audit:
  - Material weaknesses: **No**
  - Significant deficiencies: **None reported**
- e) Type of report issued on compliance for major program: **Unmodified**
- f) Audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?: **No**
- g) Major program:
  - Research and Development Cluster – various CFDA numbers
- h) Dollar threshold used to distinguish between Type A and Type B programs: **\$2,513,827**
- i) Auditee qualified as a low-risk auditee: **Yes**

**(2) Findings Relating to the Financial Statements Reported in Accordance with *Government Auditing Standards***

None.

**(3) Findings and Questioned Costs Relating to Federal Awards**

None.



KPMG LLP  
Two Financial Center  
60 South Street  
Boston, MA 02111

## Independent Auditors' Report

The Board of Trustees  
The Jackson Laboratory:

### *Report on the Consolidated Financial Statements*

We have audited the accompanying consolidated financial statements of The Jackson Laboratory (the Laboratory), which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of activities and consolidated cash flows for the years then ended, and the related notes to the consolidated financial statements.

### *Management's Responsibility for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditors' Responsibility*

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Opinion*

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Laboratory as of December 31, 2019 and 2018, and the changes in its consolidated net assets and its consolidated cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated May 19, 2020, on our consideration of the Laboratory's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Laboratory's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Laboratory's internal control over financial reporting and compliance.

KPMG LLP

May 19, 2020

**THE JACKSON LABORATORY**

Consolidated Balance Sheets

December 31, 2019 and 2018

(Dollars in thousands)

<b>Assets</b>	<b>2019</b>	<b>2018</b>
Cash and equivalents	\$ 2,533	8,406
Short-term investments, at fair value	197,058	194,234
Accounts receivable, net	46,119	45,190
Contributions receivable, net	2,429	4,457
Other assets	29,911	24,710
Long-term investments, at fair value	306,404	261,889
Long-lived assets, net	<u>527,122</u>	<u>485,875</u>
Total assets	\$ <u>1,111,576</u>	<u>1,024,761</u>
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 54,129	56,567
Deposits and deferred revenue	9,335	9,510
Bonds and note payable, net	206,720	213,548
Accrued postretirement obligations	<u>6,088</u>	<u>5,192</u>
Total liabilities	<u>276,272</u>	<u>284,817</u>
Net assets:		
Without donor restrictions	763,438	672,815
With donor restrictions	<u>71,866</u>	<u>67,129</u>
Total net assets	<u>835,304</u>	<u>739,944</u>
Total liabilities and net assets	\$ <u>1,111,576</u>	<u>1,024,761</u>

See accompanying notes to consolidated financial statements.

**THE JACKSON LABORATORY**  
Consolidated Statement of Activities  
Year ended December 31, 2019  
(Dollars in thousands)

	<u>Without donor restrictions</u>	<u>With donor restrictions</u>	<u>Total</u>
Operating activities:			
Revenue and other support:			
Grants and research contracts	\$ 107,626	—	107,626
Contributions	956	1,627	2,583
Genetic resources and clinical and research services	317,789	—	317,789
Long-term investment return utilized	3,650	2,015	5,665
Other investment return	4,714	—	4,714
Other revenue	2,389	—	2,389
	<hr/>	<hr/>	<hr/>
Total revenue	437,124	3,642	440,766
Net assets released from restrictions	4,777	(4,777)	—
	<hr/>	<hr/>	<hr/>
Total revenue and other support	441,901	(1,135)	440,766
Expenses:			
Research	141,086	—	141,086
Genetic resources and clinical and research services	198,304	—	198,304
Training	8,378	—	8,378
Institutional support	59,162	—	59,162
	<hr/>	<hr/>	<hr/>
Total expenses	406,930	—	406,930
Increase (decrease) in net assets from operating activities	34,971	(1,135)	33,836
Nonoperating activities:			
Grants and contributions for capital and long-term investments	19,399	1,466	20,865
Long-term investment gain above amounts utilized	36,337	4,406	40,743
Other, net	(84)	—	(84)
	<hr/>	<hr/>	<hr/>
Increase in net assets from nonoperating activities	55,652	5,872	61,524
Increase in net assets	90,623	4,737	95,360
Net assets, beginning of year	672,815	67,129	739,944
Net assets, end of year	<u>\$ 763,438</u>	<u>71,866</u>	<u>835,304</u>

See accompanying notes to consolidated financial statements.

**THE JACKSON LABORATORY**  
Consolidated Statement of Activities  
Year ended December 31, 2018  
(Dollars in thousands)

	<u>Without donor restrictions</u>	<u>With donor restrictions</u>	<u>Total</u>
Operating activities:			
Revenue and other support:			
Grants and research contracts	\$ 96,184	—	96,184
Contributions	1,079	3,218	4,297
Genetic resources and clinical and research services	285,102	—	285,102
Long-term investment return utilized	3,178	1,891	5,069
Other investment return	1,932	—	1,932
Other revenue	2,193	—	2,193
	<hr/>	<hr/>	<hr/>
Total revenue	389,668	5,109	394,777
Net assets released from restrictions	4,003	(4,003)	—
	<hr/>	<hr/>	<hr/>
Total revenue and other support	393,671	1,106	394,777
Expenses:			
Research	138,642	—	138,642
Genetic resources and clinical and research services	165,051	—	165,051
Training	8,499	—	8,499
Institutional support	54,540	—	54,540
	<hr/>	<hr/>	<hr/>
Total expenses	366,732	—	366,732
Increase in net assets from operating activities	26,939	1,106	28,045
Nonoperating activities:			
Grants and contributions for capital and long-term investments	7,855	2,898	10,753
Long-term investment loss above amounts utilized	(17,901)	(3,250)	(21,151)
Realized gain on termination of interest-rate swaps	601	—	601
Realized gain on forgiveness of Connecticut Innovations forgivable loans	8,724	—	8,724
Other	58	—	58
	<hr/>	<hr/>	<hr/>
Decrease in net assets from nonoperating activities	(663)	(352)	(1,015)
Increase in net assets	26,276	754	27,030
Net assets, beginning of year	646,539	66,375	712,914
Net assets, end of year	\$ <u>672,815</u>	<u>67,129</u>	<u>739,944</u>

See accompanying notes to consolidated financial statements.

**THE JACKSON LABORATORY**  
Consolidated Statements of Cash Flows  
Years ended December 31, 2019 and 2018  
(Dollars in thousands)

	<u>2019</u>	<u>2018</u>
Cash flows from operating activities:		
Increase in net assets	\$ 95,360	27,030
Adjustments to reconcile increase in net assets to cash provided by operating activities:		
Depreciation and amortization	41,656	35,494
Gain on forgiveness of Connecticut forgivable loans	—	(8,724)
Loss on debt extinguishment	—	508
Termination of interest rate swap agreements	—	(3,655)
Realized and unrealized net investment (gains)/loss	(39,673)	30,700
Realized gain on interest-rate swaps	—	(601)
Loss/(gain) on disposal of long-lived assets	757	(795)
Contributions restricted for long-term investment and assets	(3,046)	(2,328)
Changes in operating assets and liabilities	(8,216)	(13,855)
Net cash provided by operating activities	<u>86,838</u>	<u>63,774</u>
Cash flows from investing activities:		
Acquisition and construction of long-lived assets	(81,543)	(71,964)
Proceeds from sales of investments	267,826	257,247
Purchases of investments	(312,935)	(300,126)
Net cash used in investing activities	<u>(126,652)</u>	<u>(114,843)</u>
Cash flows from financing activities:		
Repayment of bonds	(6,415)	(36,925)
Proceeds from bonds	—	159,585
Bond issuance costs	—	(1,419)
Repayment of note payable	(133)	(127)
Draws under Connecticut Innovations forgivable loans prior to loan forgiveness	—	886
Contributions from Connecticut Innovations restricted for long-term assets subsequent to loan forgiveness	—	3,721
Contributions restricted for long-term investment and assets	3,046	2,328
Net cash (used in) provided by financing activities	<u>(3,502)</u>	<u>128,049</u>
Net (decrease)/increase in cash and equivalents	(43,316)	76,980
Cash, cash equivalents and restricted cash beginning of year	<u>105,997</u>	<u>29,017</u>
Cash, cash equivalents and restricted cash end of year	<u>\$ 62,681</u>	<u>105,997</u>
Cash paid for interest	\$ 8,623	4,651

See accompanying notes to consolidated financial statements.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

#### **(1) Background**

The Jackson Laboratory (the Laboratory) is a not-for-profit independent research organization focusing on research to advance human health. The purposes of the Laboratory are scientific, medical, charitable, and educational. The Laboratory strives to discover precise genomic solutions for disease and empower the global biomedical community in its shared quest to improve human health. This mission is carried out through: (1) conducting basic biomedical research; (2) training and educating scientists worldwide; and (3) developing and providing scientific services, genetic resources, and genetic and clinical information related to genetic resources to the global scientific community.

The Laboratory's financial results include the operations of its wholly-owned US subsidiary, Jackson Laboratory Holdings, LLC (LLC) and LLC's wholly-owned subsidiary, The Jackson Laboratory Medical Science and Technology (Shanghai) Co., Ltd., incorporated under Chinese law. All intercompany transactions have been eliminated in consolidation.

#### **(2) Summary of Significant Accounting Policies**

##### **(a) Basis of Presentation**

The Laboratory presents its consolidated financial statements on the accrual basis in accordance with U.S. generally accepted accounting principles (GAAP). All amounts presented in the notes to the consolidated financial statements are in thousands.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Management estimates, requiring the application of significant judgments, include obligations under a postretirement plan, liabilities under self-insured plans, allowances for uncollectible receivables and certain alternative investments.

##### **(b) Classification of Net Assets**

The Laboratory follows the reporting requirements of GAAP which require that net assets be classified for reporting purposes based on the existence or absence of donor-imposed restrictions. This is accomplished by classifying net assets into two classes: without donor restrictions and with donor restrictions. Descriptions of the two net asset categories and the types of transactions affecting each category follow:

- Without Donor Restrictions – Net assets that are not subject to donor-imposed restrictions. This net asset category principally consists of revenues and related expenses associated with the core activities of the Laboratory: conduct of sponsored research, genetic resources and clinical and research services, and training. Additionally, changes in this category include investment returns on funds without donor restrictions, including those designated by the Board of Trustees (the Board) to function as an endowment, restricted gifts whose donor-imposed restrictions were met during the fiscal year, and previously restricted gifts and grants for buildings and equipment that have been placed in service, as well as the gain on forgiveness of Connecticut Innovations, Inc. (CI) forgivable loans.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

- With Donor Restrictions – Net assets subject to donor-imposed restrictions that will be met either by actions of the Laboratory or the passage of time. This net asset category consists of gifts for which donor-imposed restrictions have not been met in the year of receipt, including gifts and grants for buildings and equipment not placed in service; endowment, pledges, and investment return on endowments funds; and endowments where the principal may be expended over a stated period of time (term endowments). Expirations of restrictions on net assets with donor restrictions are reported as net assets released from restrictions.

Also included in this category are net assets subject to donor-imposed restrictions, including gifts and pledges wherein donors stipulate that the corpus of the gift be held in perpetuity and that only the income be made available for program operations and other purposes.

Revenue is reported as an increase in net assets without donor restrictions unless its use is limited by donor-imposed restrictions or it is a pledge and included in net assets with donor restrictions until collected. Expenditures of net assets with donor restrictions are reported in the program where expended with the release of the restriction shown as a decrease in net assets with donor restrictions and an offsetting increase in net assets without donor restrictions.

#### (c) Revenue

The Laboratory follows the provisions of ASU No. 2014-09, *Revenue from Contracts with Customers* (Topic 606), which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, the Laboratory follows the provisions of ASU No. 2018-08, *Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made* (ASU 2018-08), which provides guidance as to whether the Laboratory should account for a grant (or similar transaction) as a contribution or as an exchange transition. A summary of the Laboratory's specific revenue recognition practices follows:

- *Revenue from Provision of Genetic Resources and Clinical and Research Services*

The Laboratory recognizes revenue from providing genetic resources and clinical and research services when the resources are shipped or the services are provided; these revenues are included in Genetic Resources and Clinical and Research Services revenue. Accounts receivable from such activities are reported net of allowance for uncollectible accounts.

- *Revenue from Grants and Research Contracts*

Grants and contracts awarded by federal and other sponsors, which generally are considered nonexchange transactions restricted by sponsors for certain purposes, are recognized as revenue when qualifying expenditures are incurred or other conditions under the agreements are met. The Laboratory has elected the simultaneous release policy available under ASU 2018-08, which allows a not-for-profit organization to recognize a restricted contribution directly in net assets without donor restrictions if the restriction is met in the same period that the revenue is recognized. Payments received in advance of expenditures are recorded as deferred revenue until expended. The Laboratory received approximately 76% and 78%, respectively, of its revenue from grants and contracts from the National Institutes of Health (NIH) for the years ended December 31, 2019 and 2018. CI research and operating grants provided 17% and 15% of the grant revenue in 2019 and 2018, respectively. Indirect costs are billed and recovered in accordance with the terms of the grant

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

agreements and represented \$35,190 and \$31,447, respectively, of revenue from grants for the years ended December 31, 2019 and 2018. Most NIH grants reimburse for indirect costs at an agreed percentage of direct costs incurred. CI reimburses eligible costs up to an annual maximum amount. The Laboratory applies the CI grant funds first to direct costs and then to indirect costs.

- *Revenue from Contributions*

Contributions, including unconditional promises to give, are recognized at fair value and increase net assets in the period received. Written promises to give that are scheduled to be received after the balance sheet date are shown as increases in net assets with donor restrictions and are reclassified to net assets without donor restrictions when the purpose or time restrictions are met. Promises to give subject to donor-imposed stipulations that the corpus be maintained permanently are recognized as increases in net assets with donor restrictions. Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions to be received after one year are discounted at rates commensurate with the estimated risk of receipt of the pledge. Amortization of the discount is recorded as additional contribution revenue in the appropriate net asset category.

Contributions of cash or other assets that must be used to acquire long-lived assets or the contribution of long-lived assets are reported in nonoperating support as a component of net assets with donor restrictions until the assets are placed in service.

**(d) Functional Classification of Expenses**

Program services consist of research, genetic resources and clinical and research services, and training. Expenses are presented on the consolidated statements of activities on a functional or programmatic basis, consisting of direct costs and indirect facility-related costs. Facility-related expenses, including costs for the operation and maintenance of long-lived assets, financing costs and depreciation, are allocated on the basis of square footage utilized by each of the programs. Facility-related costs related to information technology are allocated primarily on the basis of the estimated level of effort.

**THE JACKSON LABORATORY**

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Functional expenses incurred by type for the years ended December 31, 2019 and 2018 are presented below:

<b>December 31, 2019</b>					
	<b>Research</b>	<b>Genetic resources and clinical and research services</b>	<b>Training</b>	<b>Institutional support</b>	<b>Total</b>
Salaries and wages	\$ 63,834	74,977	2,688	27,447	168,946
Benefits	20,095	23,603	846	8,640	53,184
Employee recruitment, training, memberships and subscriptions	1,515	997	436	2,507	5,455
Purchased services and stipends	9,837	5,423	1,369	8,611	25,240
Supplies and shipping	15,277	42,217	555	914	58,963
Maintenance, utilities and insurance	10,174	14,667	678	3,568	29,087
Travel and meals	2,504	4,091	836	2,669	10,100
Interest expense	371	5,398	31	118	5,918
Depreciation	17,111	21,342	877	2,606	41,936
Other expenses	368	5,589	62	2,082	8,101
<b>Total</b>	<b>\$ 141,086</b>	<b>198,304</b>	<b>8,378</b>	<b>59,162</b>	<b>406,930</b>

<b>December 31, 2018</b>					
	<b>Research</b>	<b>Genetic resources and clinical and research services</b>	<b>Training</b>	<b>Institutional support</b>	<b>Total</b>
Salaries and wages	\$ 63,335	64,529	2,806	25,683	156,353
Benefits	18,826	19,181	834	7,634	46,475
Employee recruitment, training, memberships and subscriptions	1,292	590	86	2,170	4,138
Purchased services and stipends	8,733	3,111	1,571	7,712	21,127
Supplies and shipping	15,219	38,245	556	1,179	55,199
Maintenance, utilities and insurance	11,039	12,574	676	3,300	27,589
Travel and meals	2,310	3,070	999	2,593	8,972
Interest expense	1,168	3,516	57	270	5,011
Depreciation	16,554	15,662	838	2,705	35,759
Other expenses	166	4,573	76	1,294	6,109
<b>Total</b>	<b>\$ 138,642</b>	<b>165,051</b>	<b>8,499</b>	<b>54,540</b>	<b>366,732</b>

**THE JACKSON LABORATORY**

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

All direct and indirect costs of fundraising are expensed as incurred and are included in institutional support in the consolidated statements of activities. Direct fundraising expenses were \$5,175 and \$5,074 for the years ended December 31, 2019 and 2018, respectively.

**(e) Operating and Nonoperating Activities**

The consolidated statements of activities report changes in net assets from operating and nonoperating activities.

Operating activities consist of the Laboratory's ongoing research and training programs, including the provision of genetic resources and clinical and research services. Included in operating revenue is investment return appropriated to support operations under the endowment income spending formula approved by the Board, as described in note 5(c). Also included in operating revenue are research grant reimbursements of \$869 and \$444 for the years ended December 31, 2019 and 2018, for the purchase of equipment that became the property of the Laboratory upon acquisition. Depreciation charged to operating activities from research grant-funded equipment was \$447 and \$383 for the years ended December 31, 2019 and 2018, respectively.

Nonoperating revenue includes items not related to the Laboratory's recurring activities or revenue that may not be used for operations. Contributions for the acquisition of long-lived assets, net assets released from restrictions for the acquisition of long-lived assets, unrestricted bequests, investment return in excess of the amount appropriated under the Laboratory's spending formula, and grants to acquire land, buildings, and equipment are all reported as nonoperating activities. Postretirement plan charges above periodic benefit costs and the gain from the forgiveness of the CI forgivable loans are also all presented as nonoperating activities.

**(f) Cash and Cash Equivalents**

Cash and cash equivalents include highly liquid investments with original maturities of three months or less when purchased, excluding amounts whose use is limited by internal designation.

The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheet that sums to the total of such amounts as shown on the consolidated statement of cash flows as of December 31:

	<b>2019</b>	<b>2018</b>
Restricted cash included in short-term investments on the consolidated balance sheets whose use is limited (note 3)	\$ 3,003	44,646
Cash included in short-term investments on the consolidated balance sheets	57,145	52,945
Cash and cash equivalents as reported in the consolidated balance sheets	2,533	8,406
Total cash, cash equivalents and restricted cash as shown in the consolidated statement of cash flows	\$ 62,681	105,997

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

#### **(g) Self-Insurance Reserves**

The Laboratory is self-insured for healthcare benefits offered to active employees who meet eligibility requirements. These costs are accounted for on an accrual basis, which requires estimates to be made for claims incurred but not yet reported as of the consolidated balance sheet date.

#### **(h) Long-Lived Assets**

Long-lived assets are reported at cost at date of acquisition or at fair value at date of donation in the case of gifts. For assets placed in service, depreciation is provided using the straight-line method over the estimated useful lives of the assets. The cost of normal maintenance and repairs that does not add to the value of the asset or materially extend asset lives is not capitalized.

Depreciation is provided on a straight-line basis over the following estimated useful lives:

	<u>Years</u>
Buildings and improvements	15–50
Land improvements	5–15
Equipment and software	3–15

Management reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of a long-lived asset may not be recoverable. Management determined that no long-lived assets were impaired as of December 31, 2019 and 2018.

The Laboratory receives awards from various granting agencies that allow for the purchase of certain assets, scientific equipment and construction of buildings. These assets are depreciated in accordance with the aforementioned policy. The assets become the property of the Laboratory upon acquisition, unless the grant or funding agreement specifically states otherwise. Grant-funded assets are typically restricted as to use and disposal.

#### **(i) Income Taxes**

The Laboratory is a not-for-profit organization as described in Section 501(c)(3) of the Internal Revenue Code (the Code), as amended, and is generally exempt from income taxes pursuant to the Code. In accordance with GAAP, the Laboratory assesses whether there are uncertain tax positions and determined that there were no uncertain tax positions that would have a material effect on the consolidated financial statements.

#### **(j) Fair Value Measurements**

The Laboratory determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

- **Level 1 inputs:** Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

- **Level 2 inputs:** Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
- **Level 3 inputs:** Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The fair value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs. In determining fair value, the Laboratory utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Levels are determined based on the aforementioned hierarchy, except for investments measured using net asset value (NAV) as a practical expedient to estimate fair value, as described in note 3.

It is the Laboratory's policy to review and reflect transfers between levels as of the consolidated financial statement reporting date. Transfers between different levels of the fair value hierarchy are recorded as of the end of the reporting period.

The categorization of an investment within the fair value hierarchy is based on the inputs described above and does not necessarily correspond to the Laboratory's management's perceived risk of that investment. Moreover, the methods used by management may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Laboratory believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments and nonfinancial assets and liabilities could result in a different fair value measurement at the reporting date.

#### **(k) Recent Accounting Pronouncements**

In November 2016, the FASB issued ASU No. 2016-18, *Restricted Cash*, which requires that a statement of cash flows explain the changes during the period in total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Laboratory adopted ASU 2016-18 retrospectively as of January 1, 2018 to include restricted and short-term investment cash amounts within the statement of cash flows.

#### **(l) Reclassification of Prior Year Amounts**

Certain other amounts as disclosed in the prior year have been reclassified to conform to the current year presentation.

### **(3) Investments**

#### **(a) Overall Investment Objective**

The overall investment objective of the Laboratory is to invest its long-term assets in a prudent manner to achieve a long-term rate of return sufficient to fund a portion of its annual operating activities, and increase investment value after inflation. The investment objective for short-term investments is preservation of value and liquidity, relying primarily on highly rated short-term interest-bearing investments. The Laboratory diversifies its long-term investments among various asset classes incorporating multiple strategies and managers. The Investment Committee oversees the Laboratory's endowment in accordance with the investment policy statement.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

#### **(b) Basis of Reporting**

Investments, including endowment and operating investments without donor restrictions are reported at estimated fair value. If an investment is held directly by the Laboratory and an active market with quoted prices exists, the market price of an identical security is used as the reported fair value. Reported fair values for shares in registered mutual funds are based on share prices reported by the funds as of the last business day of the fiscal year. The Laboratory's interests in commingled investment funds (multiple strategies) are generally reported at the net asset value (NAV) reported by the fund managers, which is used as a practical expedient to estimate the fair value of the Laboratory's interest therein, unless it is probable that all or a portion of the investment will be sold for an amount different from NAV.

#### **(c) Classification in the Fair Value Hierarchy**

The Laboratory owns interests in alternative investment funds that are generally reported at the NAV reported by the fund managers, unless the fund has a readily determinable fair value that is used as a practical expedient to estimate the fair value of the Laboratory's interest therein, or it is probable that all or a portion of the investment will be sold for an amount different from the NAV. Such valuations are determined by fund managers who generally consider variables such as operating results, comparable earnings multiples, projected cash flows, recent sales prices, and other pertinent information, and also may reflect discounts for the liquid nature of certain investments held. As of December 31, 2019 and 2018 the Laboratory had no plans or intentions to sell investments at amounts different from NAV.

The inputs or methodology used for valuing or classifying investments for financial reporting purposes are not necessarily an indication of the risk associated with investing in those investments or a reflection on the liquidity of each fund's underlying assets and liabilities.

There were no transfers between Level 1 and Level 2 for the fiscal years ended December 31, 2019 and 2018.

**THE JACKSON LABORATORY**

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The following tables summarize the Laboratory's investments by major category in the fair value hierarchy as of December 31, 2019 and 2018, as well as related strategy, liquidity and funding commitments:

	December 31, 2019			Total
	Level 1	Level 2	NAV or equivalent	
Short-term investments:				
Cash, money market accounts and certificates of deposits <sup>1</sup>	\$ 89,059	—	—	89,059
U.S. and global fixed income funds	107,999	—	—	107,999
Total short-term investments	197,058	—	—	197,058
Long-term investments (endowment):				
Money market accounts and certificates of deposit	49,120	—	—	49,120
U.S. and global fixed income funds	26,653	—	—	26,653
Equities:				
U.S. mid and large cap value funds	101,059	—	—	101,059
Global large cap	100,311	—	—	100,311
Total equities	201,370	—	—	201,370
Multiple hedged strategies <sup>2</sup>	—	—	9,273	9,273
Private equity and real assets <sup>2</sup>	—	—	19,988	19,988
Total long-term investments	277,143	—	29,261	306,404
Total	\$ 474,201	—	29,261	503,462

<sup>1</sup> Includes \$3,003 in cash from 2018 bond proceeds designated for working capital purposes (note 8(a)).

<sup>2</sup> The redemption or liquidation is monthly to locked up. The lock-up periods have various terms with extensions of one to two years. As of December 31, 2019, the average remaining life of these partnerships is approximately eight years.

**THE JACKSON LABORATORY**  
Notes to Consolidated Financial Statements  
December 31, 2019 and 2018

	December 31, 2018			
	Level 1	Level 2	NAV or equivalent	Total
Short-term investments:				
Cash, money market accounts and certificates of deposits <sup>1</sup>	\$ 118,578	—	—	118,578
Corporate bonds	—	1,011	—	1,011
U.S. and global fixed income funds	74,645	—	—	74,645
Total short-term investments	193,223	1,011	—	194,234
Long-term investments (endowment):				
Money market accounts and certificates of deposit	617	—	—	617
U.S. and global fixed income funds	21,421	—	—	21,421
Equities:				
U.S. mid and large cap value funds	70,190	—	—	70,190
Global large cap	70,261	—	—	70,261
Total equities	140,451	—	—	140,451
Multiple hedged strategies <sup>2</sup>	78,582	—	9,940	88,522
Private equity and real assets <sup>2</sup>	—	—	10,878	10,878
Total long-term investments	241,071	—	20,818	261,889
Total	\$ 434,294	1,011	20,818	456,123

<sup>1</sup> Includes \$44,646 in cash from 2018 bond proceeds designated for working capital purposes (note 8(a)).

<sup>2</sup> The redemption or liquidation is monthly to locked up. The lock-up periods have various terms with extensions of one to two years. As of December 31, 2018, the average remaining life of these partnerships is approximately eight years.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

#### (d) Commitments

Private equity investments are generally made through private limited partnerships. Under the terms of the partnership agreements, the Laboratory makes a commitment of a specific amount of capital to a partnership and is obligated to remit committed funding periodically when capital calls are exercised by the General Partner as the partnership executes on its investment strategy. Private equity funds are typically structured with investment periods of three-to-seven years. The aggregate amounts of unfunded commitments associated with private limited partnerships as of December 31, 2019 and 2018 were \$34,970 and \$21,205, respectively. The timing and amount of future capital calls expected to be exercised in any particular future year is uncertain.

#### (4) Financial Assets and Liquidity Resources

As of December 31, 2019 and 2018 financial assets and liquidity resources available within one year for general expenditure, such as operating and program expenditure, scheduled principal and interest payments on debt, and capital constructions costs not financed with debt, were as follows:

	2019	2018
Financial assets:		
Cash and cash equivalents	\$ 2,533	8,406
Contributions and accounts receivable, net	46,770	46,839
Short-term investments	197,058	149,588
Budgeted endowment payouts:		
Board-designated	4,909	3,651
Donor-restricted	2,188	2,015
Total financial assets available within one year	253,458	210,499
Liquidity resources:		
Bank line of credit	50,000	25,000
Total financial assets and liquidity resources available within one year	\$ 303,458	235,499

The Laboratory actively manages its resources utilizing a combination of short, medium and long-term operating investment strategies to align its cash inflows with anticipated outflows in accordance with policies approved by the Board. As disclosed in note 8(a), the Laboratory may draw upon an unsecured revolving credit facility to manage cash flows.

Additionally, as of December 31, 2019 and 2018, the Laboratory had an additional \$235,691 and \$200,463, respectively, in Board-designated endowments not budgeted for spending which is available for general expenditure with Board approval.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

#### **(5) Endowment**

The Laboratory's endowment consisted of approximately 73 individual donor-restricted funds, as well as Board-designated funds held for the long-term support of the Laboratory's mission.

Both donor-restricted and Board-designated endowment funds were invested with a total return objective and long-term goal of attaining an average annualized nominal return equal to, or above the rate of inflation, based on the Consumer Price Index (CPI), plus the Laboratory's spending rate.

##### **(a) Interpretation of Relevant Law**

The Laboratory is subject to the Maine Uniform Prudent Management of Institutional Funds Act (MUPMIFA).

For reporting purposes the Laboratory classifies as net assets with donor restrictions the historical value of donor-restricted endowment funds, which includes: (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) changes to the endowment made in accordance with the direction of the applicable donor instrument. Also included in net assets with donor restrictions is accumulated appreciation on donor-restricted endowment funds which are available for expenditure in a manner consistent with the standard of prudence prescribed by MUPMIFA, and deficiencies associated with funds where the value of the fund has fallen below the original value of the gift as disclosed in note 5(d).

##### **(b) Investment Strategies**

The endowment provides financial support for programs through the generation of income and gains while preserving capital for future support. The endowment is managed to maximize long-term, risk-adjusted investment returns. The investment objective for both donor-restricted and Board-designated funds can be met through a common investment pool with liquidity sufficient to meet the needs of the Laboratory. Only the Board-designated funds may be used to meet liquidity covenants as required by the Laboratory's creditors or bondholders.

##### **(c) Endowment Spending Policy**

The Laboratory employs a total-return approach to endowment management. Income and dividends are used to fund spending first, with net realized and unrealized appreciation providing incremental funding as needed. Taking into consideration the factors continued in MUPMIFA for the appropriation and accumulation of endowment funds, the annual spending policy distribution rate from the endowment shall be a target percentage as adopted by the Investment Committee from time to time, of the twelve-quarter moving average market value, with the final quarter in the spending formula determined on December 31 of the last audited year preceding the fiscal year of spending. The spending distribution is reviewed and approved annually by the Investment Committee in conjunction with the recommended adoption of the annual budget by the Finance Committee.

##### **(d) Funds with Deficiencies**

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the historic dollar value of permanently restricted contributions. Deficiencies of this nature are reported in net assets with donor restrictions when they occur. There were no individual funds with deficiencies at December 31, 2019. Deficiencies totaled \$48 at December 31, 2018.

**THE JACKSON LABORATORY**

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

**(e) Net Assets by Type of Fund and Changes in Endowment Investments**

Net assets by type of fund consisted of the following at December 31, 2019 and 2018:

	<b>2019</b>			
	<b>Without donor restrictions</b>	<b>With donor restrictions</b>		<b>Total</b>
		<b>Underwater funds</b>	<b>Other funds</b>	
Donor-restricted endowments:				
Historical gift value	\$ —	—	25,420	25,420
(Depreciation)/appreciation	—	—	40,384	40,384
Board-designated endowments	240,600	—	—	240,600
Total	\$ <u>240,600</u>	<u>—</u>	<u>65,804</u>	<u>306,404</u>

	<b>2018</b>			
	<b>Without donor restrictions</b>	<b>With donor restrictions</b>		<b>Total</b>
		<b>Underwater funds</b>	<b>Other funds</b>	
Donor-restricted endowments:				
Historical gift value	\$ —	1,636	20,738	22,374
(Depreciation)/appreciation	—	(48)	35,449	35,401
Board-designated endowments	204,114	—	—	204,114
Total	\$ <u>204,114</u>	<u>1,588</u>	<u>56,187</u>	<u>261,889</u>

Changes in endowment assets for the years ended December 31, 2019 and 2018 are as follows:

	<b>December 31, 2019</b>		
	<b>Without donor restrictions</b>	<b>With donor restrictions</b>	<b>Total</b>
Endowment, December 31, 2018	\$ 204,114	57,775	261,889
Cash contributions	—	3,046	3,046
Investment return	39,987	6,421	46,408
Long-term investment return utilized	(3,650)	(2,015)	(5,665)
In-transit transactions	149	577	726
Endowment, December 31, 2019	\$ <u>240,600</u>	<u>65,804</u>	<u>306,404</u>

**THE JACKSON LABORATORY**  
Notes to Consolidated Financial Statements  
December 31, 2019 and 2018

	<b>December 31, 2018</b>		
	<b>Without donor restrictions</b>	<b>With donor restrictions</b>	<b>Total</b>
Endowment, December 31, 2018	\$ 108,927	58,754	167,681
Cash contributions	—	2,328	2,328
Board transfer from operating funds to endowment	113,050	—	113,050
Investment return	(14,723)	(1,357)	(16,080)
Long-term investment return utilized	(3,178)	(1,891)	(5,069)
In-transit transactions	38	(59)	(21)
Endowment, December 31, 2019	<u>\$ 204,114</u>	<u>57,775</u>	<u>261,889</u>

In-transit transactions are due to timing of transfers between the Laboratory's operational accounts and endowment accounts for gifts received and reimbursement of expenditures. Gifts are shown as the amount of cash received and therefore include the collection of pledge payments and exclude uncollected pledges.

**(6) Accounts Receivable**

Accounts receivable consisted of the following as of December 31, 2019 and 2018:

	<b>2019</b>	<b>2018</b>
Due from provision of genetic resources and services	\$ 30,524	32,092
Amounts reimbursable under grants and contracts	7,892	9,275
Miscellaneous accounts receivable	8,970	5,503
	<u>47,386</u>	<u>46,870</u>
Less allowance for uncollectibles	(1,267)	(1,680)
Accounts receivable, net	<u>\$ 46,119</u>	<u>45,190</u>

**THE JACKSON LABORATORY**  
Notes to Consolidated Financial Statements  
December 31, 2019 and 2018

**(7) Long-Lived Assets**

Long-lived assets consisted of the following as of December 31, 2019 and 2018:

	<u>2019</u>	<u>2018</u>
Land and improvements	\$ 12,757	11,226
Buildings and improvements	648,543	619,676
Construction in progress	67,666	45,004
Equipment and software	<u>186,254</u>	<u>171,398</u>
	915,220	847,304
Less accumulated depreciation	<u>(388,098)</u>	<u>(361,429)</u>
Long-lived assets, net	<u>\$ 527,122</u>	<u>485,875</u>

The change in accounts payable for acquisition and construction of long-lived assets was a decrease of \$2,397 for the year ended December 31, 2019 and a decrease of \$7,303 for the year ended December 31, 2018.

Commitments to third parties for the purchase of equipment, space renovation and construction projects were \$42,881 and \$15,424 as of December 31, 2019 and 2018, respectively.

**(8) Debt**

**(a) Bonds and Note Payable**

Bonds and note payable consisted of the following as of December 31, 2019 and 2018:

	<u>2019</u>	<u>2018</u>
Series 2018 taxable bonds	\$ 152,885	157,520
Association of Bay Area Government for California fixed rate revenue bonds (ABAG Series 2012 bonds)	<u>50,300</u>	<u>52,080</u>
	203,185	209,600
Plus unamortized premium	3,416	3,753
Debt issuance costs	<u>(1,510)</u>	<u>(1,566)</u>
Bonds payable, net	205,091	211,787
Note payable for real estate purchase	<u>1,629</u>	<u>1,761</u>
Bonds and note payable, net	<u>\$ 206,720</u>	<u>213,548</u>

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

On March 19, 2018, the Laboratory issued taxable bonds in the amount of \$159,585. A portion of the proceeds were utilized to refund \$33,165 of a former bond series. The remainder of the proceeds are intended for capital improvements. The bonds have a stated rate of fixed interest ranging from 2.25% to 4.334%, payable semiannually, over a 30 year term. Interest expense incurred during 2019 and 2018 on the taxable bonds totaled \$3,777 and \$2,301, net of capitalized interest of \$2,390 and \$2,590, respectively. At December 31, 2019 and 2018 accrued interest of \$3,053 and \$3,113, respectively, is included in accrued expenses on the consolidated balance sheet. The remaining bond proceeds on hand of \$3,003 and \$44,646 at December 31, 2019 and 2018, respectively, are included in short-term investments on the consolidated balance sheet.

Subsequent to the bond issuance in 2018, the Laboratory utilized \$3,655 of bond proceeds to terminate the outstanding interest-rate swaps related to the former bond series. The Laboratory recognized a gain on the termination of the swaps of \$601, resulting from the excess of the swaps' fair value over the termination fees paid in 2018.

The ABAG Series 2012 bonds were issued with a par amount of \$60,290 and a premium of \$6,066 at fixed interest rates ranging from 2.5% to 5% over a 25-year term. The proceeds were used to refund existing ABAG bonds and fund the further fit-out of the Laboratory's Sacramento facility. Interest expense incurred during 2019 and 2018 totaled \$2,328 and \$2,059, respectively.

In connection with the purchase of property located contiguous to the Laboratory's Bar Harbor campus, the Laboratory entered into a \$2,260 fifteen year note with the seller of the property. The note bears a fixed interest rate of 4% and requires monthly mortgage amortization payments.

As of December 31, 2018 the laboratory entered into a one-year, \$25,000 unsecured line of credit with a financial institution, to provide general working capital needs and other corporate purposes. The line of credit was increased to \$50,000 during 2019 and extended to December 31, 2020. Interest is payable monthly at the rate of LIBOR plus 0.45%. The Laboratory did not utilize the unsecured line of credit during the year ended December 31, 2019 or 2018. The Laboratory is required to maintain certain financial, rating agency and reporting covenants.

#### **(b) *CI Forgivable Loans***

On January 5, 2012, the Laboratory entered into several agreements with various sub-units of the state of Connecticut to build a 183,500 square foot laboratory and operate a genomics medicine research program in Farmington, Connecticut. The major agreements include a funding agreement with CI, a ground lease with the University of Connecticut Health Center (UHC), and a collaboration agreement with the University of Connecticut (UConn).

The CI funding agreement provided forgivable loans to construct a building and for the purchase of equipment, as well as \$99,000 in grant commitments to support research and development over ten years.

On June 26, 2018 the Laboratory met the loan forgiveness requirements pursuant to the CI funding agreement and CI forgave the outstanding loans. The Laboratory realized a net gain on loan forgiveness of \$8,724, representing the fair value of the loan balances plus additional loan draws through and accrued interest as of June 26, 2018. The gain is included in the nonoperating section of the consolidated statement of activities for the year ended December 31, 2018.

## THE JACKSON LABORATORY

### Notes to Consolidated Financial Statements

December 31, 2019 and 2018

As part of the transaction, UCHC provided a 99-year ground lease for the building site. The ground lease contains a provision whereby the land will transfer to the Laboratory upon reaching 600 employees in Connecticut. The ground lease also includes limitations on the sale and use of the facility. A collaboration agreement with UConn covers joint faculty appointments, grant applications, UConn assignment and funding of faculty to be located at the Laboratory's Farmington site, and other related matters.

As of December 31, 2019 and 2018, the Laboratory had incurred \$182,039 and \$169,656, respectively, in project-related costs, which are included in construction in progress, buildings and improvements, and equipment. Subsequent to loan forgiveness, the Laboratory may continue to draw funds up to an amount equivalent to the original loan amounts without incurring additional debt. The Laboratory drew funds totaling \$12,383 for 2019 and \$3,721 for 2018 subsequent to June 26, 2018; these funds are realized as a contribution and are included in the nonoperating section of the consolidated statement of activities for the year ended December 31, 2019 and 2018. As of December 31, 2019 the Laboratory has an available balance of \$9,466 for future draws under the agreement. The contributions include no funds held in escrow by CI as retainage as of December 31, 2019 and 2018.

#### **(c) Maturities of Long-Term Debt**

Maturities of long-term debt as of December 31, 2019, were as follows:

	<u>Amounts due</u>
Year ending December 31:	
2020	\$ 6,743
2021	6,969
2022	7,194
2023	7,131
2024	7,382
Thereafter	<u>169,395</u>
Total	<u>\$ 204,814</u>

#### **(9) Employee Benefits**

##### **(a) Defined Contribution Retirement Plan**

Subject to meeting certain eligibility requirements, all employees participate in a defined contribution 403(b) retirement plan administered by the Laboratory. Contribution expense was \$13,585 and \$12,702 for the years ended December 31, 2019 and 2018, respectively.

**THE JACKSON LABORATORY**

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

**(b) Postretirement Medical Plan**

The Laboratory maintains a non-contributory postretirement medical plan covering certain retired employees with hire dates before 2003 and faculty members eligible to retire on May 31, 2008, and their dependents. Other than the payment of current benefits totaling \$724 and \$498 in the years ended December 31, 2019 and 2018, respectively, the Laboratory has not funded the postretirement plan. The benefit obligation as of December 31, 2019 and 2018, respectively, is \$6,088 and \$5,192, and is reported as accrued postretirement obligations on the consolidated balance sheet.

**(c) Deferred Compensation Program**

The Laboratory maintains a nonqualified salary deferral plan authorized under Section 457(b) of the Internal Revenue Code. The Laboratory holds an investment approximately matching the employee investment selections to assure funding is available to meet future liabilities. The liability of \$7,145 and \$5,422 at December 31, 2019 and 2018, respectively, is included in accounts payable and accrued expenses. The investments valued at \$7,145 and \$5,459 at December 31, 2019 and 2018, respectively, are included in other assets.

The Laboratory also maintains a deferred compensation program under Section 457(f) of the Internal Revenue Code for management and certain highly compensated employees under which a portion of the employee's compensation is deferred and vested over time. The liability of \$721 and \$628 at December 31, 2019 and 2018, respectively, is included in accounts payable and accrued expenses, and the corresponding assets are included in other assets.

**(10) Net Assets**

Net assets without donor restrictions include Board-designated endowments that are used to support the Laboratory's strategic initiatives and general operations. The Laboratory classifies gift pledges based on donor purpose restriction. Unrestricted pledges are shown as a component of net assets with donor restrictions until collected. Net assets with donor restrictions consisted of the following at December 31:

	<b>2019</b>	<b>2018</b>
Donor-restricted endowments:		
Research	\$ 20,246	17,612
Training	1,211	939
Other programs	881	877
General purpose	3,082	2,946
Pledges receivable for endowment	786	2,396
Total endowment	26,206	24,770
Purpose and time-restricted, and other:		
Unappropriated return	40,384	35,401
Other	5,276	6,958
Total net assets with donor restrictions	\$ 71,866	67,129

**THE JACKSON LABORATORY**  
Notes to Consolidated Financial Statements  
December 31, 2019 and 2018

**(11) Commitments and Contingencies**

The Laboratory leases laboratory and office space and other equipment under leases accounted for as operating leases. Some of these leases have renewal options. Total rental expense was \$504 and \$321 for the years ended December 31, 2019 and 2018, respectively. Estimated future minimum lease payments under noncancelable facility and equipment operating leases as of December 31, 2019 are as follows:

	<u>Amounts due</u>
Year ending December 31:	
2020	\$ 586
2021	511
2022	504
2023	194
2024	72
Thereafter	168
Total	\$ 2,035

**(12) Legal Claims**

The Laboratory is subject to certain legal proceedings and claims that arise in the ordinary course of conducting its activities. While it is not possible to predict accurately or determine the eventual outcome of such actions, management believes that the outcome of proceedings will not have a material adverse effect on the Laboratory's financial position.

**(13) Related Party Transactions**

Members of the Laboratory's Board and senior management may, from time to time, be associated, either directly or indirectly, with companies doing business with the Laboratory. The Laboratory has a written conflict of interest policy that requires, among other things, that no member of the Board may participate in any decision in which he or she has a material financial interest.

Each member of the Board and senior management is required to certify compliance with the conflict of interest policy on an annual basis as well as disclose any potential related party transactions to the General Counsel's Office and the Audit and Enterprise Risk Management Committee.

**(14) Subsequent Events**

The Laboratory has evaluated subsequent events from the consolidated balance sheet date of December 31, 2019 through May 19, 2020, the date on which the consolidated financial statements were issued, and determined there are no other items to disclose.

In March 2020, the broader U.S. economy was affected by the COVID-19 pandemic. The impact on the Laboratory's finances, if any, cannot yet be determined. The U.S. financial markets have also suffered as a result of the COVID-19 pandemic and therefore negative changes in the fair value of financial instruments held as of December 31, 2019 may have occurred and be material.

**THE JACKSON LABORATORY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended December 31, 2019

Federal grantor/pass-through grantor/program title	Federal CFDA number	Direct or pass-through identifying number	Passed through to subrecipients	Total federal expenditures
Research and Development Cluster:				
Department of Health and Human Services:				
Direct awards, National Institutes of Health (NIH):				
Environmental Health	93.113	R01 ES029916A	\$ —	365,767
Human Genome Research	93.172	R00 HG008179B	—	273,677
Human Genome Research	93.172	R01 HG009900A	—	871,154
Human Genome Research	93.172	R25 HG007053B	—	99,803
Human Genome Research	93.172	R25 HG010611A	—	42,463
Human Genome Research	93.172	U24 HG007497C	263,923	706,442
Human Genome Research	93.172	U41 HG000330H	—	3,475,052
Human Genome Research	93.172	U41 HG007497B	169,014	227,735
Human Genome Research	93.172	UM1 HG009409A	76,295	1,566,126
Research Related to Deafness and Communication Disorders	93.173	R01 DC004301D	12,032	246,472
Research Related to Deafness and Communication Disorders	93.173	R01 DC015242A	—	356,538
Research Related to Deafness and Communication Disorders	93.173	R01 DC018304A	—	41,934
Research Related to Deafness and Communication Disorders	93.173	R13 DC017388A	—	1,906
Research Related to Deafness and Communication Disorders	93.173	R21 DC016376B	—	175,717
Alcohol Research Programs	93.273	R01 AA018776B	109,914	427,273
Drug Abuse and Addiction Research Programs	93.279	K99 DA043573A	—	150,700
Drug Abuse and Addiction Research Programs	93.279	P50 DA039841A	498,867	3,201,324
Drug Abuse and Addiction Research Programs	93.279	R01 DA028420B	—	439,523
Drug Abuse and Addiction Research Programs	93.279	R01 DA037927A	—	652,820
Drug Abuse and Addiction Research Programs	93.279	R01 DA045401A	—	209,973
Drug Abuse and Addiction Research Programs	93.279	R13 DA032192C	—	25,000
Drug Abuse and Addiction Research Programs	93.279	R21 DA048634A	—	183,988
Drug Abuse and Addiction Research Programs	93.279	U01 DA041668A	—	720,970
Drug Abuse and Addiction Research Programs	93.279	U01 DA043809A	13,488	733,832
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	R25 EB022365A	—	6,197
Trans-NIH Research Support	93.310	U54 DK107967A	10,823	429,109
Trans-NIH Research Support	93.310	R25 EB022365A	—	62,604
Trans-NIH Research Support	93.310	DP2 GM126893A	—	103,263
Trans-NIH Research Support	93.310	R25 GM123516A	—	128,845
Trans-NIH Research Support	93.310	U01 CA239108A	120,639	345,568
Trans-NIH Research Support	93.310	UM1 OD023222B	26,878	594,903
Research Infrastructure Programs	93.351	R13 OD010920F	—	16,844
Research Infrastructure Programs	93.351	P40 OD011102D	—	745,083
Research Infrastructure Programs	93.351	R13 OD023013A	23,049	23,049
Research Infrastructure Programs	93.351	R21 OD023800A	—	164,597
Research Infrastructure Programs	93.351	R21 OD023803A	—	151,228
Research Infrastructure Programs	93.351	R21 OD024941A	—	236,342
Research Infrastructure Programs	93.351	R21 OD027052A	7,567	128,534
Research Infrastructure Programs	93.351	R24 OD011190B	—	265,707
Research Infrastructure Programs	93.351	R24 OD011190C	—	162,227
Research Infrastructure Programs	93.351	R24 OD021325A	—	1,296,759
Research Infrastructure Programs	93.351	S10 OD026870A	—	419,271
Research Infrastructure Programs	93.351	U42 OD010921B	—	1,255,747
Research Infrastructure Programs	93.351	U42 OD026635A	26,971	576,393
Research Infrastructure Programs	93.351	U54 OD020351A	159,383	2,048,023
Research Infrastructure Programs	93.351	UM1 OD023222B	—	6,245,922
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	U24 CA224067A	259,235	1,005,045
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	U24 CA224067B	—	288,576
Cancer Cause and Prevention Research	93.393	R01 CA190121B	127,295	169,605
Cancer Treatment Research	93.395	R01 CA219880A	10,133	695,961
Cancer Biology Research	93.396	R00 CA178206B	—	129,708
Cancer Biology Research	93.396	R00 CA188093B	—	231,104
Cancer Biology Research	93.396	R01 CA089713D	—	1,069,204
Cancer Biology Research	93.396	R01 CA195712A	4,550	4,550
Cancer Biology Research	93.396	R01 CA230031A	—	556,992
Cancer Biology Research	93.396	R01 CA237208A	—	37,140
Cancer Biology Research	93.396	R21 CA224422A	104,449	169,426
Cancer Centers Support Grants	93.397	P30 CA034196G	—	2,234,111
Cancer Centers Support Grants	93.397	P30 CA034196H	—	149,841
Cancer Research Manpower	93.398	K99 CA226387A	—	107,215
Cancer Research Manpower	93.398	R25 CA122819D	—	160,307
Cancer Research Manpower	93.398	R25 CA172010A	—	46,041
Cancer Research Manpower	93.398	R25 CA233420A	—	70,588
Cardiovascular Diseases Research	93.837	R37 HL077796C	—	300,868
Blood Diseases and Resources Research	93.839	R01 HL134043A	143,991	648,851
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R01 AR049288D	(11,753)	(11,753)
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R21 AR075174A	4,716	26,416
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	F32 DK120298A	—	61,403
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK046266E	—	159,322
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK095735C	12,416	389,931
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK100692B	—	229,501
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK102918B	37,038	425,688

**THE JACKSON LABORATORY**

Supplementary Schedule of Expenditures of Federal Awards

Year ended December 31, 2019

<u>Federal grantor/pass-through grantor/program title</u>	<u>Federal CFDA number</u>	<u>Direct or pass-through identifying number</u>	<u>Passed through to subrecipients</u>	<u>Total federal expenditures</u>
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK117137A	\$ 18,465	323,467
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK118072A	—	521,750
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	F31 NS100328A	—	23,545
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS054154D	—	392,631
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS064013B	—	165,884
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS102414A	354,157	622,953
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R21 NS105116A	131,404	268,894
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R21 NS114873A	—	75,108
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R24 NS098523A	—	414,861
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R25 NS078795C	—	38,100
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R61 NS115129A	—	31,717
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.900	U54 NS105539A	383,686	2,525,821
Allergy, Immunology and Transplantation Research	93.855	R01 AI121920A	18,457	406,969
Allergy, Immunology and Transplantation Research	93.855	R01 AI141609A	—	341,005
Allergy, Immunology and Transplantation Research	93.855	R01 AI142086A	24,945	288,207
Allergy, Immunology and Transplantation Research	93.855	R21 AI133440A	—	255,383
Allergy, Immunology and Transplantation Research	93.855	R21 AI135221A	—	204,619
Allergy, Immunology and Transplantation Research	93.855	R21 AI145383A	—	119,839
Allergy, Immunology and Transplantation Research	93.855	U01 AI124297A	108,205	559,301
Allergy, Immunology and Transplantation Research	93.855	U19 AI142733A	328,368	1,197,169
Biomedical Research and Research Training	93.859	P01 GM099640B	—	42,128
Biomedical Research and Research Training	93.859	R00 GM110332B	—	286,294
Biomedical Research and Research Training	93.859	R01 GM070683C	47,973	111,434
Biomedical Research and Research Training	93.859	R01 GM070683D	40,573	110,283
Biomedical Research and Research Training	93.859	R01 GM115518A	—	485,715
Biomedical Research and Research Training	93.859	R01 GM125736A	86,662	443,112
Biomedical Research and Research Training	93.859	R01 GM127531A	140,422	360,660
Biomedical Research and Research Training	93.859	R25 GM113979A	—	65,518
Biomedical Research and Research Training	93.859	R25 OD020205A	9,467	310,802
Biomedical Research and Research Training	93.859	R35 GM124922A	23,617	353,200
Biomedical Research and Research Training	93.859	R35 GM124998A	67,480	290,572
Biomedical Research and Research Training	93.859	R35 GM128717A	—	426,272
Biomedical Research and Research Training	93.859	R35 GM133415A	—	121,854
Biomedical Research and Research Training	93.859	R35 GM133495A	—	115,594
Biomedical Research and Research Training	93.859	R35 GM133562A	—	185,636
Biomedical Research and Research Training	93.859	R35 GM133711A	—	147,498
Biomedical Research and Research Training	93.859	R35 GM133724A	—	150,775
Child Health and Human Development Extramural Research	93.865	R01 HD073077B	—	(4)
Child Health and Human Development Extramural Research	93.865	R01 HD093778A	—	437,239
Child Health and Human Development Extramural Research	93.865	R25 HD079344A	—	10,973
Child Health and Human Development Extramural Research	93.865	R25 HD079344B	—	145,883
Child Health and Human Development Extramural Research	93.865	T32 HD007065H	—	189,282
Child Health and Human Development Extramural Research	93.865	P41 HD062499B	—	2,214,296
Aging Research	93.866	P30 AG038070B	8,358	759,790
Aging Research	93.866	R01 AG052608A	118,444	680,778
Aging Research	93.866	R01 AG054180A	187,845	667,140
Aging Research	93.866	R01 AG055104A	34,733	708,138
Aging Research	93.866	R01 AG057914A	146,948	1,840,893
Aging Research	93.866	R13 AG060708A	638	1,404
Aging Research	93.866	R13 AG064968A	—	21,547
Aging Research	93.866	R56 AG060746A	—	11,970
Aging Research	93.866	RF1 AG051496A	335,062	829,327
Aging Research	93.866	RF1 AG063755A	—	275,824
Aging Research	93.866	U01 AG022308C	—	1,371,236
Aging Research	93.866	U01 AG022308D	—	437,021
Aging Research	93.866	U24 AG066346A	—	14,567
Aging Research	93.866	RF1 AG059778A	—	1,117,181
Vision Research	93.867	R01 EY011721D	—	344,658
Vision Research	93.867	R01 EY011996D	—	747,762
Vision Research	93.867	R01 EY019943B	—	176,512
Vision Research	93.867	R01 EY019943C	—	236,095
Vision Research	93.867	R01 EY027305A	—	546,186
Vision Research	93.867	R01 EY027860A	12,573	629,992
Vision Research	93.867	R01 EY028175A	—	367,639
Vision Research	93.867	R21 EY027894A	17,237	231,601

**THE JACKSON LABORATORY**

Supplementary Schedule of Expenditures of Federal Awards

Year ended December 31, 2019

Federal grantor/pass-through grantor/program title	Federal CFDA number	Direct or pass-through identifying number	Passed through to subrecipients	Total federal expenditures
Vision Research	93.867	R01 EY028561A	\$ —	353,686
Medical Library Assistance	93.879	R21 LM012615A	113,355	232,703
Total direct awards, NIH			<u>4,969,987</u>	<u>68,343,934</u>
Pass-through awards, NIH:				
Children's Hospital Medical Center Oral Diseases and Disorders Research	93.121	R35 DE027557A CHMC	—	35,580
The Forsyth Institute Oral Diseases and Disorders Research	93.121	R37 DE016937C Forsyth	—	7,263
University of Connecticut Health Center Oral Diseases and Disorders Research	93.121	T90 DE021989B UCHC	—	30,233
California Institute of Technology Human Genome Research	93.172	U24 HG002223F CIT	—	435,587
California Institute of Technology Human Genome Research	93.172	U24 HG010859A CALTECH	—	223,697
The Broad Institute, Inc Human Genome Research	93.172	UM1 HG009435A Broad Inst	—	741,736
University of Maryland Human Genome Research	93.172	U41 HG008735A Maryland	—	86,251
University Of Southern California Human Genome Research	93.172	U41 HG002273F USC	—	693,034
University Of Washington Human Genome Research	93.172	R01 HG010169A UW	—	81,260
Purdue University Research Related to Deafness and Communication Disorders	93.173	R21 DC016732A Purdue	—	16,923
University of Southern California Research on Healthcare Costs, Quality and Outcomes	93.226	R01 HS025690A USC	—	22,911
Trustees of the University of Pennsylvania National Center on Sleep Disorders Research	93.233	P01 HL094307B PENN	—	69,554
Emory University Drug Abuse and Addiction Research Programs	93.279	DP1 DA042103A Emory U	—	13,994
Emory University Drug Abuse and Addiction Research Programs	93.279	R01 DA042742A Emory U	—	7,468
Virginia Commonwealth University Drug Abuse and Addiction Research Programs	93.279	U01 DA045299A VCU	—	378,159
University of Connecticut Health Center Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	U01 EB028898A UCHC	—	107,386
Oregon Health & Science University National Center for Advancing Translational Sciences	93.350	U24 TR002306A OHSU	—	186,330
Tufts University School of Medicine National Center for Advancing Translational Sciences	93.350	UL1 TR002544A Tufts	—	22,738
Tufts University School of Medicine National Center for Advancing Translational Sciences	93.350	UL1 TR002544A Tufts	—	27,166
Oregon State University Research Infrastructure Programs	93.351	R24 OD011883B OSU	—	98,954
University Of Massachusetts Research Infrastructure Programs	93.351	R24 OD026440A UMA	—	54,678
University of Utah 21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	U54 CA224076A UTAH	—	30,950
Brigham and Women's Hospital Nursing Research	93.361	R21 NR017256A BWH	—	16,194
Moffitt Cancer Center Cancer Cause and Prevention Research	93.393	R01 CA219389A Moffit	—	17,340
University of Southern California Cancer Cause and Prevention Research	93.393	R01 CA207972A USC	—	44,739
Cold Spring Harbor Laboratory Cancer Treatment Research	93.395	U10 CA180944A CSHL HR	—	756
Cold Spring Harbor Laboratory Cancer Treatment Research	93.395	U10 CA180944A CSHL LIU	—	24,050
Cold Spring Harbor Laboratory Cancer Treatment Research	93.395	U10 CA180944A CSHL PR	—	18,120
Cold Spring Harbor Laboratory Cancer Treatment Research	93.395	U10 CA180944A CSHL PR	—	12,733
Cold Spring Harbor Laboratory Cancer Treatment Research	93.395	U10 CA180944A CSHL SM	—	12,733
Cyteir Therapeutics, Inc. Cancer Treatment Research	93.395	R42 CA183197B Cyteir	—	8,379
Cold Spring Harbor Laboratory Cancer Biology Research	93.396	U01 CA224013A CSHL PR	—	461,759
University California San Diego Cancer Biology Research	93.396	U24 CA220341A UCSD	—	67,734
Washington University at St. Louis Cancer Biology Research	93.396	R01 CA204115A WU	—	72,804
Yale University Cancer Biology Research	93.396	R01 CA227473A Yale	—	192,266

**THE JACKSON LABORATORY**

Supplementary Schedule of Expenditures of Federal Awards

Year ended December 31, 2019

<u>Federal grantor/pass-through grantor/program title</u>	<u>Federal CFDA number</u>	<u>Direct or pass-through identifying number</u>	<u>Passed through to subrecipients</u>	<u>Total federal expenditures</u>
Trustees of the University of Pennsylvania Cardiovascular Diseases Research	93.837	P01 HL094307B PENN	\$ —	31,925
University of Connecticut Health Center Cardiovascular Diseases Research	93.837	R01 HL142787A UCHC	—	368,070
University of North Carolina Cardiovascular Diseases Research	93.837	OT3 HL142479A UNCCH	—	2,036
University of Pittsburgh Cardiovascular Diseases Research	93.837	R01 HL132024A UPitt	—	96,672
University of Pittsburgh Cardiovascular Diseases Research	93.837	R01 HL142788A UPitt	—	40,790
Trustees of Indiana University Lung Diseases Research	93.838	U01 HL121812A Indiana Univ	—	25,678
Trustees of Indiana University Lung Diseases Research	93.838	U01 HL121831A Indiana Univ	—	115,378
Azitra Inc Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R43 AR073562A Azitra	—	74,247
Joan & Sanford I Weill Medical College of Cornell University Arthritis, Musculoskeletal and Skin Diseases Research	93.846	P50 AR070594A Cornell	—	693,279
The Research Foundation of SUNY Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R21 AR071878A SUNY	—	31,346
Thomas Jefferson University Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R01 AR072695A ThomJe	—	28,693
University of Connecticut Health Center Arthritis, Musculoskeletal and Skin Diseases Research	93.846	R01 AR060636C UCHC	—	177,135
Medical College of Wisconsin Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK088831B MCW	—	47,002
University Of Massachusetts Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	U01 DK104218B UMA	—	35,733
University of Wisconsin Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	R01 DK101573A UW	—	25,432
The Trustees of Columbia University Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS091118B COLUMBIA	—	35,725
University of Connecticut Health Center Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS102633B UCHC	—	1,844
University of California San Diego Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS094637B UCSD	—	13,297
University of Iowa Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	R01 NS055272E Iowa	—	29,665
Brigham and Women's Hospital Allergy, Immunology and Transplantation Research	93.855	R01 AI141529A BWH	—	1,846
Nationwide Children's Hospital Allergy, Immunology and Transplantation Research	93.855	U01 AI131386A NCH	—	484,375
New England Blood Center Allergy, Immunology and Transplantation Research	93.855	U01 AI124260A NYBC	—	70,882
University of Connecticut Health Center Allergy, Immunology and Transplantation Research	93.855	R01 AI135128A UCHC	—	30,602
University of Massachusetts Allergy, Immunology and Transplantation Research	93.855	R01 AI132963A UMA	—	294,921
University Of Massachusetts Allergy, Immunology and Transplantation Research	93.855	UC4 DK104218A UMA	—	117,213
Yale University Allergy, Immunology and Transplantation Research	93.855	R01 AI136942A Yale	—	50,470
d'Vinci Interactive, Inc Biomedical Research and Research Training	93.859	R43 GM133222A d'Vinci	—	13,000
Georgia Regents University Biomedical Research and Research Training	93.859	R01 GM121551A UGA	—	36,757
MDI Biological Laboratory Biomedical Research and Research Training	93.859	P20 GM104318C	—	71,453
University of Connecticut Health Center Biomedical Research and Research Training	93.859	R00 GM120453B UCHC	—	249,975
University of Connecticut Health Center Biomedical Research and Research Training	93.859	R35 GM133600A UCHC	—	31,049
University of Delaware Biomedical Research and Research Training	93.859	R01 GM080646D UDL	—	109,950
University of Michigan Biomedical Research and Research Training	93.859	R01 GM124251A U Michigan	—	138,028
Massachusetts General Hospital Child Health and Human Development Extramural Research	93.865	P01 HD068250B MGH Bult	—	210,710
Duke University Aging Research	93.866	UH2 AG056925A Duke	—	84,479
Emory University Aging Research	93.866	U54 AG065187A Emory	—	1,623

**THE JACKSON LABORATORY**  
 Supplementary Schedule of Expenditures of Federal Awards  
 Year ended December 31, 2019

Federal grantor/pass-through grantor/program title	Federal CFDA number	Direct or pass-through identifying number	Passed through to subrecipients	Total federal expenditures
Regents of the University of California Aging Research	93.866	RF1 AG057558A UC	\$ —	55,543
The Trustees of Columbia University Aging Research	93.866	RF1 AG057473A Columbia U	—	8,186
TissueVision, Inc. Aging Research	93.866	R44 AG062017A TissueVis	—	71,063
Trustees of Indiana University Aging Research	93.866	U01 AG060900A Indiana Univ	—	202,220
Trustees of Indiana University Aging Research	93.866	U54 AG054345A IU	—	2,963,345
Trustees of Indiana University Aging Research	93.866	U54 AG054345A Indiana	—	8,365
Trustees of Indiana University Aging Research	93.866	U54 AG054345A Indiana	—	1,954
University of Connecticut Health Center Aging Research	93.866	R01 AG052962A UCHC	—	247,411
University of Connecticut Health Center Aging Research	93.866	R01 AG058814A UCHC	—	32,889
University of Arizona Aging Research	93.866	R01 AG057931A Arizona	—	132,852
University of Pittsburgh Aging Research	93.866	R13 AG060708B UPitt	—	25,987
Trustees of Indiana University Aging Research	93.866	U54 AG054345A IU	—	229,527
Northwestern University Vision Research	93.867	R01 EY025799A NWU C03	—	44,322
Northwestern University Vision Research	93.867	R01 EY025799A NWU C04	—	77,881
University of Rochester Vision Research	93.867	R01 EY027701A Univ Rochester	—	273,450
Total pass-through awards, NIH			—	12,567,734
Total Department of Health and Human Services			4,969,987	80,911,668
National Science Foundation (NSF):				
Direct awards, NSF:				
Biological Sciences	47.074	DBI 1851697	—	147,235
Pass-through awards, NSF:				
Azitra Inc.				
Engineering	47.041	1853071 NSF Azitra	—	13,637
Total NSF			—	160,872
Department of Defense (DOD):				
Direct awards, DOD:				
Military Medical Research and Development	12.420	DOD A Palucka W81XWH1710010	—	487,892
Military Medical Research and Development	12.420	DOD Courtois W81XWH1910130	—	109,868
Military Medical Research and Development	12.420	DOD E Liu W81XWH1710005	—	561,862
Military Medical Research and Development	12.420	DOD G Ren W81XWH1810013	—	406,616
Military Medical Research and Development	12.420	DOD M Stitzel W81XWH1610130	—	4,479
Military Medical Research and Development	12.420	DOD Oh W81XWH1810229	110,908	377,093
Military Medical Research and Development	12.420	DOD Stitzel W81XWH1810401	—	409,480
Military Medical Research and Development	12.420	DOD Ucar W81XWH1810402	—	241,834
Military Medical Research and Development	12.420	DOD Verhaak W81XWH1910246	—	122,558
Total direct awards, DOD			110,908	2,721,682
Total Department of Defense			110,908	2,721,682
Total Research and Development Cluster			5,080,895	83,794,222
Total expenditures of federal awards			\$ 5,080,895	83,794,222

See accompanying notes to supplementary schedule of expenditures of federal awards.

## THE JACKSON LABORATORY

Notes to Supplementary Schedule of Expenditures of Federal Awards

Year ended December 31, 2019

### (1) Definition of Reporting Entity and Basis of Presentation

The accompanying schedule of expenditures of federal awards presents expenditures of all federal awards programs of The Jackson Laboratory (the Laboratory), including awards passed through to the Laboratory from other organizations (i.e., primary recipients), for the year ended December 31, 2019. The schedule is presented using the modified cash basis of accounting. Negative amounts (if any) on the schedule represent cash transfer adjustments to expenditures reported in a prior year. The Laboratory has not elected to utilize the 10% de minimus indirect cost rate in Part 200.514 of the Uniform Guidance.

For purposes of the schedule, federal awards include grants, contracts, and similar agreements entered into directly between the Laboratory and agencies and departments of the federal government and all subawards to the Laboratory by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The awards are categorized in accordance with the provisions of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the schedule presents only a selected portion of the operations of the Laboratory, it is not intended to and does not present the financial position, changes in net assets or cash flows of the Laboratory.